<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0220920</article-id>
<article-id pub-id-type="publisher-id">PONE-D-19-14313</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Vascular medicine</subject><subj-group><subject>Blood pressure</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antihypertensives</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxicity</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxicity</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmaceutics</subject><subj-group><subject>Drug therapy</subject><subj-group><subject>Drug administration</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antihypertensive drugs</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drug screening</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Computational chemistry</subject><subj-group><subject>Molecular docking</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical compounds</subject><subj-group><subject>Organic compounds</subject><subj-group><subject>Alcohols</subject><subj-group><subject>Ethanol</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic chemistry</subject><subj-group><subject>Organic compounds</subject><subj-group><subject>Alcohols</subject><subj-group><subject>Ethanol</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Antihypertensive activity, toxicity and molecular docking study of newly synthesized xanthon derivatives (xanthonoxypropanolamine)</article-title>
<alt-title alt-title-type="running-head">Novel xanthones with antihypertensive activity</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9298-0696</contrib-id>
<name name-style="western">
<surname>Goshain</surname>
<given-names>Omprakash</given-names>
</name>
<role content-type="http://credit.casrai.org/">Writing – original draft</role>
<xref ref-type="aff" rid="aff001"/>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6834-9781</contrib-id>
<name name-style="western">
<surname>Ahmed</surname>
<given-names>Bahar</given-names>
</name>
<role content-type="http://credit.casrai.org/">Supervision</role>
<xref ref-type="corresp" rid="cor001">*</xref>
<xref ref-type="aff" rid="aff001"/>
</contrib>
</contrib-group>
<aff id="aff001"><addr-line>Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard University, New Delhi,India</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Shahid</surname>
<given-names>Mohammad</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Aligarh Muslim University, INDIA</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">bahaarahmad40@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>14</volume>
<issue>8</issue>
<elocation-id>e0220920</elocation-id>
<history>
<date date-type="received">
<day>1</day>
<month>6</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>7</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Goshain, Ahmed</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0220920"/>
<abstract>
<sec id="sec001">
<title>Context</title>
<p>Xanthone derivatives have been reported to possess a wide range of biological properties. In effort to search new effective antihypertensive compounds, we have synthesizednovel xanthone derivatives (xanthonoxypropanolamines) and got patent for these compounds (The Patent Office, Government of India, S. No.: 011–016308, Patent No.: 250538).</p>
</sec>
<sec id="sec002">
<title>Objective</title>
<p>In the present work, we attempted to establish the antihypertensive activity, toxicity and molecular docking study forthese newly synthesized compounds (1a, 1b and 2).</p>
</sec>
<sec id="sec003">
<title>Materials and method</title>
<p>The preliminary antihypertensive screening was performed by administering synthesized compounds and standard drugs intraperitonially and orally into wistar rats. The change in systolic, diastolic and the mean blood pressure before and after the treatment of the drugs was measured on a Digital LE-S100 Blood Pressure Meter by Tail-cuff method non-invasively. Toxicity studies were carried out after oral administration of synthesized compounds to rats at doses of 25, 50, and 100mg/kg. The serum samples were tested for different toxicity parameters such as liver function test, kidney function test etc. The docking simulations of all the compounds were performed using Maestro, version 9.4 implemented from Schrodinger software suite.</p>
</sec>
<sec id="sec004">
<title>Results and discussion</title>
<p>The result showed that the compound 1a, 1b and 2 have greater antihypertensive activity with almost equal or less toxicity profile in comparison to standard drug Propranolol and Atenolol. The docking score for the compound <bold>1b</bold> was found <bold>-9.1</bold> while for compound <bold>1a</bold> and <bold>2</bold> were found <bold>-8.7</bold> and <bold>-8.6</bold> respectively.</p>
</sec>
<sec id="sec005">
<title>Conclusion</title>
<p>These novel compounds i.e. 1a, 1b, and 2 have greater antihypertensive activity in comparison to standard drugs Propranolol and Atenolol. All these compounds do not have any toxicity.</p>
</sec>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>UGC, New Delhi</institution>
</funding-source>
<award-id>Grant no: F.40-276/2011 (SR)</award-id>
<principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6834-9781</contrib-id>
<name name-style="western">
<surname>Ahmed</surname>
<given-names>Bahar</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This research work was funded by University Grants Commission, Bhadurshah Zafar Marg, New Delhi, India, Grant no: F.40-276/2011 (SR).</funding-statement>
</funding-group>
<counts>
<fig-count count="8"/>
<table-count count="4"/>
<page-count count="13"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the manuscript.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec006" sec-type="intro">
<title>Introduction</title>
<p>Xanthones represent a large group of heterocyclic compounds including natural, semi synthetic and totally synthetic structures. Chemically, xanthonic nucleus corresponds to dibenzo-γ- pyrone. Xanthone molecules, having a variety of substituents on the different carbon of the nucleus, constitute a group of compounds with a broad spectrum of biological activities. Xanthone derivatives have been reported to possess a wide range of biological properties including antimalarial [<xref ref-type="bibr" rid="pone.0220920.ref001">1</xref>], anticonvulsant [<xref ref-type="bibr" rid="pone.0220920.ref002">2</xref>], anticancer [<xref ref-type="bibr" rid="pone.0220920.ref003">3</xref>], antidiabetic [<xref ref-type="bibr" rid="pone.0220920.ref004">4</xref>], antioxidant [<xref ref-type="bibr" rid="pone.0220920.ref005">5</xref>], anti-inflammatory [<xref ref-type="bibr" rid="pone.0220920.ref006">6</xref>], and antihypertensive [<xref ref-type="bibr" rid="pone.0220920.ref007">7</xref>, <xref ref-type="bibr" rid="pone.0220920.ref008">8</xref>] activities. In effort to search new effective antihypertensive compounds, we have synthesized eleven xanthone derivatives (xanthonoxypropanolamines) and got patent for these compounds [<xref ref-type="bibr" rid="pone.0220920.ref009">9</xref>]. In the present work, we attempted to establish the antihypertensive activity and toxicity of these compounds (1a, 1b and 2)and performed exhaustive preliminary antihypertensive screening study and different toxicity study including lever function test, kidney function test, cardiac function test, lipid function test, Acetylcholine esterase, glutathione, catalase, superoxide dismutase (SOD) estimation and Thiobarbituric acid reactive substances (TBARS) Assay. The preliminary antihypertensive screening data of these compounds showed excellent antihypertensive profile. Different toxicity test data were compared with standard drug propranolol and atenolol. It was observed that these compounds are almost as safe as propranolol and atenolol.</p>
<p>Molecular docking, in the field of molecular modeling, is a method which gives best fit orientation of a ligand (drug) to their target molecules (receptors) by generating different score for different orientation. These score is known as docking score. More negative value of docking score indicates better fit orientation [<xref ref-type="bibr" rid="pone.0220920.ref010">10</xref>]. In order to strengthen the preliminary antihypertensive screening results, here we have also reported the docking score of all the three compounds and compared with standard drug propranolol.</p>
<p>The hydroxyl propoxy xanthones (xanthonoxypropanolamines) were synthesized by using general route for the synthesis of xanthonoxypropanolamines as shown in the <xref ref-type="fig" rid="pone.0220920.g001">Fig 1</xref>. The appropriate phenols were reacted with epichlorhydrin in the presence of alkali and ethanol to produce their epoxy derivatives. Ring opening of epoxides was occurred by refluxing in ethanol to get the aryloxypropanolamines derivatives.</p>
<fig id="pone.0220920.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220920.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Synthesis of xanthonoxypropanolamines.</title>
<p><bold>1a</bold>; R = H, R<sub>1</sub> = CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> <bold>1b</bold>; R = H, R<sub>1</sub> = CH (CH<sub>3</sub>)<sub>2</sub> <bold>2</bold>; R = OH, R<sub>1</sub> = CH (CH<sub>3</sub>)<sub>2</sub>.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0220920.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec007" sec-type="materials|methods">
<title>Materials and methods</title>
<p>The melting points were determined in one side sealed melting point capillary tubes using Thomas Hoover melting point apparatus and are uncorrected. The purity of the compounds was checked by thin layer chromatography (TLC) with solvent system benzene: methanol (8:2), using iodine vapours as visualizing agents and R<sub>f</sub> values were calculated. Infra red spectra were determined on JASCO FT/IR-5300 Infrared Spectrophotometer by KBr disc method. <sup>1</sup>H-NMR (300 MHz) and <sup>13</sup>C-NMR (75 MHz) spectral studies were done on JEOL AL FTNMR Spectrophotometer using chloroform as solvent. The MS data were recorded on a Quattro micro API Waters’s mass spectrometer/ method—ESI-MS.</p>
<sec id="sec008">
<title>Chemistry</title>
<sec id="sec009">
<title>Synthesis of novel xanthonoxypropanolamines [<xref ref-type="bibr" rid="pone.0220920.ref011">11</xref>]</title>
<p><bold>General Procedure</bold></p>
<p>The appropriate phenols (i.e. heterocyclic aromatic compounds containing hydroxyl groups) were condensed with epichlorhydrin in the presence of alkali and ethanol to obtain their epoxy derivatives. Ring opening of epoxides with various amines was achieved by refluxing in ethanol to afford the aryloxypropanolamines derivatives.</p>
<p><bold>Synthesis of di and tri-hydroxy xanthones</bold></p>
<p>A mixture of <italic>o</italic>-hydroxy benzoic acid or 2, 4 dihydroxy benzoic acid, a phenol (such as catechol, pyrogallol, resorcinol, etc.), freshly fused zinc chloride (ZnCl<sub>2</sub>) and phosphorous oxychloride (POCl<sub>3</sub>) was heated on a water bath or on heating mantle (maintaining the temperature 55-70°C) for 1.5–2 hr, cooled and poured into ice water carefully in order to avoid polymerization (Grover et al., 1955). The product was filtered off, washed with 2% sodium hydrogen carbonate solution (if needed) and water, dried and crystallized from suitable solvents. The recrystallization of compounds from appropriate solvents furnished analytically pure products.</p>
<p><bold>Preparation of epoxy compounds (3-aryloxy-2, 3-epoxy propane) from the respective hydroxyl-xanthones</bold></p>
<p>Epichlorhydrin was added to a solution of hydroxyl xanthones in an aqueous ethanol containing sodium hydroxide. The reaction mixtures were heated under reflux at 60-75°C for two hours with continuous stirring. The mixtures for each respective xanthones were stirred for further three hours at room temperature. The products were poured into ice water, the oily layer was separated out and concentrated under reduced pressure (or aqueous layer was decanted after keeping overnight in a refrigerator and was left in open air for evaporation up to dryness). The epoxy compounds, wherever required, were further purified by silica gel column chromatography using benzene: methanol (80:20) as eluent.</p>
<p><bold>Preparation of [(alkyl/aryl-amino)-2-hydroxy-propoxyl]–xanthones</bold></p>
<p>The prepared epoxy derivatives of xanthones, in absolute alcohol, were added slowly in large excess of different type of alkyl/aryl amines. The molar ratio of amines and epoxides were generally taken as (500–100:1). The reaction mixtures were refluxed with stirring at least 17 to 24 hrs (in some cases up to 2–3 days) at 50-65c. The mixtures were further stirred under reflux at room temperature for 1–2 days, if needed. The products were, then, subjected to evaporate in the vacuum to remove the remaining amines. The resulting amino-alcohols were purified and recrystallized from appropriate solvents.</p>
</sec>
<sec id="sec010">
<title>Spectral data</title>
<p><bold>3, 6-Di–[3-(n-propyl-amino)-2-hydroxy-propoxy] xanthone (1a)</bold>: Obtained as jelly solid (soluble in water and chloroform), reddish brown. m.p. 103–104°C, R<sub>f</sub>: 0.32 [Benzene: Methanol (8:2)], yield: 71.6%. UV (λ max CH<sub>3</sub>OH): 304, 280, 234, 224, 215 nm. IR: nmax (KBr): 3500–3450 (OH, NH), 2950 (CH<sub>3</sub>), 2807 (CH<sub>2</sub>), 1688 (C = O), 1550 (N-H and C = C merged), 1276 (N-H), 1221(C-O, phenolic), 1156, 1047 (C-O, alcoholic), 743 (C-H, aromatic), 626 cm-1. <sup>1</sup>H NMR: (CDCl<sub>3</sub>, 300 MHz) δ 8.75 (2H, <italic>d</italic>, J = 8.0 Hz, H-1, H-8), 8.55 (2H, <italic>d</italic>, J = 2.0 Hz, H-4, H-5), 7.96 (2H, <italic>dd</italic>, J = 2.0, 8.0 Hz, H-2, H-7), 4.86 (4H, <italic>m</italic>, -OC<underline>H</underline><sub>2</sub>-1′ and -OC<underline>H</underline><sub>2</sub>-1″), 3.39 (2H, pentet, W1/2 = 17.0 Hz, -C<underline>H</underline>-2′ and C<underline>H</underline>-2″), 2.83 (4H, br<italic>m</italic>, -C<underline>H</underline><sub>2</sub>-3′ and -C<underline>H</underline>2-3″), 2.46 (2H,<italic>m</italic> N-<underline>H</underline>- 4′, and N-<underline>H</underline>-4″), 1.58 (8H, <italic>m</italic>, -C<underline>H</underline>2-C<underline>H</underline><sub>2</sub>-5′, 6′ and -C<underline>H</underline><sub>2</sub>-C<underline>H</underline><sub>2</sub>-5″, 6″), 0.87 (6H, <italic>t</italic>, J = 6.0Hz, -C<underline>H</underline><sub>3</sub>-7′ and–C<underline>H</underline><sub>3</sub>-7″). TOF MS ES+ (70 ev): <italic>m/z</italic> 458 (M+, C<sub>25</sub>H<sub>34</sub> N<sub>2</sub>O<sub>6</sub>) (12), 403 (species -a) (7), 402 (species-b) (50), 358 (species-c) (18), 294 (species-d, base peak) (100), 273 (species-e) (35), 185 (species-f) (72).</p>
<p><bold>3, 6-Di–[3-(iso-propyl-amino)-2-hydroxy-propoxy]–xanthone (1b)</bold>: Recrystallized from ethanol, soluble in water and ethanol. m. p. 101–102°C, Needle shaped long, white-reddish crystals. R<sub>f</sub>: 0.33 [Benzene: Methanol (8:2)] yield: 74.5%. UV (λ max CH<sub>3</sub>OH): 305, 296, 236, 222, 214, 211 nm. IR: nmax (KBr): 3298 (OH), 2977 (CH<sub>3</sub>), 2850 (CH<sub>2</sub>), 1651 (C = O and N-H), 1514 (C = C), 1450, 1367, 1225 (N-H), 1155 (C-O, phenolic), 760 (C = C), 566 cm-1. <sup>1</sup>H NMR: (DMSO-d6, 300 MHz): δ 8.75 (2H, <italic>d</italic>, J = 8.0 Hz, H-1, H-8), 8.55 (2H, <italic>d</italic>, J = 2.0 Hz, H-4, H-5), 7.96 (2H, <italic>dd</italic>, J = 2.0, 8.0 Hz, H-2, H-7), 3.88 (4H, <italic>brs</italic>, -OC<underline>H</underline><sub>2</sub>-1′ and -OC<underline>H</underline><sub>2</sub>-1″), 3.24 (2H, pentets, W1/2 = 15.8 Hz, -C<underline>H</underline>-2′ and C<underline>H</underline>-2″), 2.80 (4H, <italic>m</italic>, -C<underline>H</underline><sub>2</sub>-3′ and -C<underline>H</underline><sub>2</sub>-3″), 2.0 (2H, <underline><italic>s</italic></underline> N-<underline>H</underline>- 4′, and N-<underline>H</underline>-4″), 1.84 (2H, septet, W1/2 = 17.5 Hz, -C<underline>H</underline>-5′, -C<underline>H</underline>-5″), 1.18 (6H, <italic>d</italic>, J = 6.0Hz, -C<underline>H</underline><sub>3</sub>-6′ and–C<underline>H</underline><sub>3</sub>-6″), 1.01 (6H, <italic>d</italic>, J = 6.0Hz, -C<underline>H</underline><sub>3</sub>-7′ and–C<underline>H</underline><sub>3</sub>-7″). <sup>13</sup>C NMR (DMSO-d6, 75 MHz): δ 127.2 (C-1), 101.1 (C-2), 157.3 (C-3), 93.2 (C-4), 97.5 (C-5), 164.1 (C-6), 102.1 (C-7), 131.2 (C-8), 179.9 (C-9, C = O), 162.6 (C-10), 115.1 (C-11), 156.1 (C-12), 113.2 (C-13), 71.3 (C-1′, C-1″), 66.0 (C-2′, C-2″), 49.4 (C-3′, C-3″), 46.7 (C-5′, C-5″), 24.66 (C-6′, C-6″), 23.8 (C-7′, C-7″). TOF MS ES+ (70 eV): <italic>m/z</italic> 458 (M+, C<sub>25</sub>H<sub>34</sub>N<sub>2</sub>O<sub>6</sub>) (40), 414 (species-a, base peak) (100), 343 (species-b) (8) or 343 (species-c) (8), 243 (species-d) (43), 185 (species-e) (63).</p>
<p><bold>3, 6-Di–[3-(iso-propyl-amino)-2-hydroxy-propoxy] -1-hydroxy xanthone (2):</bold> Obtained the product (2b) as reddish brown semisolid, soluble in water. m.p. 98–99°C, Rf: 0.31 [Benzene: Methanol (8:2)], yield: 72.4%. UV (λ max CH<sub>3</sub>OH): 307, 260, 239, 226, 212 nm. IR: n max (KBr): 3400 (NH, OH), 2950 (CH<sub>3</sub>), 2850 (CH<sub>2</sub>), 1654 (C = O), 1545 (C = C and N-H), 1446, 1380, 1287, 1179, 1106 (N-H), 1016 (C-O, alcoholic), 827 cm<sup>-1</sup>. <sup>1</sup>H NMR (DMSO-d6, 400 MHz): δ 8.01 (1H, <italic>d</italic>, J = 2.0 Hz, H-2), 8.15 (1H, <italic>d</italic>, J = 2.0 Hz, H-4), 8.45 (<sup>1</sup>H, <italic>d</italic>, J = 2.0 Hz, H-5), 8.16 (<sup>1</sup>H, <italic>d</italic>, J = 8.5 Hz, H-8), 8.15 (1H, <italic>dd</italic>, J = 8.5, 2.0 Hz, H-7), 3.88 (4H, <italic>m</italic>, -OC<underline>H</underline><sub>2</sub>-1′ and -OC<underline>H</underline><sub>2</sub>-1″), 3.24 (2H, 2 pentets, W1/2 = 17.5 Hz, -C<underline>H</underline>-2′ and C<underline>H</underline>-2″), 2.80 (4H, <italic>m</italic>, -C<underline>H</underline><sub>2</sub>-3′ and -C<underline>H</underline><sub>2</sub>-3″), 2.50 (2H, <underline><italic>s</italic></underline> N-<underline>H</underline>- 4′, and N-<underline>H</underline>-4″), 1.84 (2H, septet W1/2 = 17.5 Hz, -C<underline>H</underline>-5′, -C<underline>H</underline>-5″), 1.18 (6H, <italic>d</italic>, J = 6.0Hz, -C<underline>H</underline><sub>3</sub>-6′ and–C<underline>H</underline><sub>3</sub>-6″), 1.01 (6H, <italic>d</italic>, J = 6.0Hz, -C<underline>H</underline><sub>3</sub>-7′ and–C<underline>H</underline><sub>3</sub>-7″). <sup>13</sup>C NMR (DMSO-d6, 75 MHz): δ 165.0 (C-1), 101.1 (C-2), 157.3 (C-3), 93.2 (C-4), 97.5 (C-5), 164.1 (C-6), 102.1 (C-7), 131.2 (C-8), 179.9 (C-9), 162.6 (C-10), 115.1 (C-11), 156.1 (C-12), 113.2 (C-13), 71.3, 70.6 (C-1′, C-1″), 67.8, 66.0 (C-2′, C-2″), 49.9, 49.4 (C-3′, C-3″), 47.2, 46.7 (C-5′, C-5″), 24.66 (C-6′, C-6″), 23.8 (C-7′, C-7″). TOF MS ES+ (70 ev): <italic>m/z</italic> 474 (M+, C<sub>25</sub>H<sub>34</sub>N<sub>2</sub>O<sub>7</sub>) (18), 434 (species-a) (12), 415 (species-b) (17), 414 (species-c, base peak) (100), 361 (species -d) (50), 300 (species-e) (15), 243 (species-f) (17), 185 (species-g) (8).</p>
</sec>
</sec>
<sec id="sec011">
<title>Antihypertensive screening</title>
<sec id="sec012">
<title>Experimental animals</title>
<p>Albino Wistar rats of either sex, weighing 180-210g, were obtained from animal house, Jamia Hamdard, Hamdard Nagar, New Delhi 110062 and kept in separated cages under standard environmental conditions of temperature 20 to 30ºC and humidity and were provided with standard rat chow and water <italic>ad libitum</italic>. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the institutional animal ethical committee regulations of Jamia Hamdard (IAEC-Jamia Hamdard). The protocol was approved by the Committee on the Ethics of Animal Experiments of Jamia Hamdard University (Reg. No.: 173/GO/Re/S/2000 /CPCSEA). All experiment was performed under diethyl ether anesthesia, and all efforts were made to minimize suffering. Cervical dislocation was used as method of sacrifice.</p>
</sec>
<sec id="sec013">
<title>Drugs</title>
<p>The standard drugs atenelol and propranolol and the methyl prednisolone acetate were procured from sigma chemicals.</p>
</sec>
<sec id="sec014">
<title>Instruments</title>
<p>The change in systolic, diastolic and the mean blood pressure before and after the treatment of the drugs was measured on a Digital LE-S100 Blood Pressure Meter in Tail-cuff method non-invasively at full cautious state of the animals and compared with the standard drugs.</p>
</sec>
<sec id="sec015" sec-type="materials|methods">
<title>Method</title>
<p>The standard drug methyl prednisolone acetate was administered by intraperitonial route at a single dose of 1 mg/ kg (body weight) to a group of rats. The control group was given only saline (NaCl, 0.9%) at the rate of 5 ml/ rat. Another group of rat was administered standard drug methyl prednisolone acetate intraperitoinally at a single dose of 1 mg/ kg followed by the administration of the test compounds intraperitonially and orally at a single dose of 10 mg/ kg each and reference drugs propranolol and atenolol 35 mg/ kg respectively. The rise in mean arterial BP and heart rate was observed at once appeared on digital pressure meter at the interval of each 15 minutes and the average change in mean blood pressure and heart rate was also calculated and recorded [<xref ref-type="bibr" rid="pone.0220920.ref012">12</xref>].</p>
</sec>
</sec>
<sec id="sec016">
<title>Toxicity study</title>
<p>The novel compounds were also evaluated for their toxicity. Liver function test [<xref ref-type="bibr" rid="pone.0220920.ref013">13</xref>]—Determination of Serum Glutamic Oxaloacetic Transaminase (SGOT); Serum Glutamic Pyruvate transaminase (SGPT); Alkaline Phosphatase ALP; was carried out after intraperitonial administration of single dose i.e. 10mg/ kg of all the tested compounds. Other toxicity studies such as kidney function test [<xref ref-type="bibr" rid="pone.0220920.ref014">14</xref>,<xref ref-type="bibr" rid="pone.0220920.ref015">15</xref>]—determination of level of urea and creatinine, cardiac function test [<xref ref-type="bibr" rid="pone.0220920.ref016">16</xref>, <xref ref-type="bibr" rid="pone.0220920.ref017">17</xref>]—determination of lactate dehydrogenase (LDH), lipid function test [<xref ref-type="bibr" rid="pone.0220920.ref018">18</xref>–<xref ref-type="bibr" rid="pone.0220920.ref021">21</xref>]—determination of triglyceride (TG),Acetylcholine esterase assay—determination of level of acetylcholine (ACH), Glutathione (GSH) assay, catalase assay, Superoxide dismutase (SOD) estimation [<xref ref-type="bibr" rid="pone.0220920.ref022">22</xref>] and Thiobarbituric acid reactive substances (TBARS) assay [<xref ref-type="bibr" rid="pone.0220920.ref023">23</xref>] were carried out after oral administration to rats at doses of 25, 50, and 100mg/kg at Deshpande Laboratories Pvt. Ltd. An ISO 9001:2008 Certified Drug Testing Laboratory CPCSEA Approved: 1410/c/11/CPCSEA, Bhopal, M.P. India.</p>
</sec>
<sec id="sec017">
<title>Molecular docking study</title>
<p>The docking simulations of all the compounds were performed using Maestro, version 9.4 implemented from Schrodinger software suite. The ligands were sketched in 3D format using build panel and were prepared for docking using ligprep application. The protein for docking study was taken from protein data bank (PDB ID: 4BVN) and prepared by removing solvent, adding hydrogen and further minimization in the presence of bound ligand using protein preparation wizard. Grids for molecular docking were generated with bound co-crystallized ligand, for the validation of docking parameters the standard ligand (propranolol) was re-docked at the catalytic site of protein and the RMSD between co-crystal and re-docked pose was found to be 0.255 A. All the three synthesized compounds were docked using Glide extra-precision (XP) mode, with up to three poses saved per molecule.</p>
</sec>
</sec>
<sec id="sec018" sec-type="conclusions">
<title>Results and discussion</title>
<sec id="sec019">
<title>Antihypertensive activity study</title>
<p>Xanthone derivatives reduce the blood pressure by blocking calcium channel and <italic>β</italic>receptors [<xref ref-type="bibr" rid="pone.0220920.ref024">24</xref>]. Synthesis of xanthonoxypropanolamines were carried out by first reaction of 2, 4-dihydroxy benzoic acid with appropriate phenol (resorcinol, phloroglucinol) in presence of freshly fused zinc chloride and POCl<sub>3</sub> which gave di and tri-hydroxy xanthones. The solution of hydroxyl xanthones in an aqueous ethanol containing sodium hydroxide and epichlorhydrin was refluxed to give epoxy compounds (3-aryloxy-2, 3-epoxy propane) in good yield (78–81%), and then the ethanolic solution of the epoxy derivatives were refluxed in large excess of different type of alkyl/ aryl amines which yielded the xanthonoxypropanolamines (<xref ref-type="fig" rid="pone.0220920.g001">Fig 1</xref>). The xanthonoxypropanolomines were purified by recrystallization with appropriate solvent. IR, <sup>1</sup>H-NMR, <sup>13</sup>C NMR and MASS spectral data of all the synthesized compounds were consistent with the assigned structures. All the synthesized compounds were screened for the antihypertensive activity and toxicity of novel compounds. The result (Tables <xref ref-type="table" rid="pone.0220920.t001">1</xref> and <xref ref-type="table" rid="pone.0220920.t002">2</xref> and Figs <xref ref-type="fig" rid="pone.0220920.g002">2</xref> and <xref ref-type="fig" rid="pone.0220920.g003">3</xref>) showed that the compound <bold>1a, 1b</bold> and <bold>2</bold> have greater activity as these compound showed <bold>11.30%, 18.8%</bold> and <bold>12.6%</bold> reduction in systolic blood pressure and <bold>21.00%, 25.4%</bold> and <bold>27.30%</bold> in mean blood pressure respectively at the doses of <bold>10 mg/kg</bold> while the standard drug Propranolol and Atenolol showed only <bold>11.70%</bold> and <bold>11.76%</bold> reduction in systolic blood pressure and <bold>11.20%</bold> and <bold>11.42%</bold> in mean blood pressure respectively at the doses of <bold>35 mg/kg</bold> on i.p administration of drugs. After oral administration of drug, the percentages of reduction in systolic blood pressure were <bold>12.00%, 19.20%</bold> and <bold>11.34%</bold> and <bold>19.00%, 20.48%</bold> and <bold>20.66%</bold> in mean blood pressure respectively by <bold>1a, 1b</bold> and <bold>2</bold> while percentages of reduction in systolic blood pressure were <bold>11.48%</bold> and <bold>10.71%</bold> and in mean blood pressure <bold>10.60%</bold> and <bold>11.52%</bold> by standard drug Propranolol and Atenolol respectively.</p>
<fig id="pone.0220920.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220920.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Activity profile curve (i.p. route).</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0220920.g002" xlink:type="simple"/>
</fig>
<fig id="pone.0220920.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220920.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Activity profile curve (oral route).</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0220920.g003" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0220920.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220920.t001</object-id>
<label>Table 1</label> <caption><title>Average effect of standard drugs and test compounds (i. p. route).</title></caption>
<alternatives>
<graphic id="pone.0220920.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0220920.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" rowspan="2">Compounds</th>
<th align="center" rowspan="2">Dose<break/></th>
<th align="center" colspan="2">Pretreated BP Induced (mmHg)</th>
<th align="center" colspan="2">After1 hr of<break/>Treatment (mmHg)</th>
<th align="center" colspan="2">Change in BP (mmHg)</th>
<th align="center" colspan="2">% Decrease in BP (mmHg)</th>
</tr>
<tr>
<th align="center">ASBP</th>
<th align="center">AMBP</th>
<th align="center">ASBP</th>
<th align="center">AMBP</th>
<th align="center">ASBP</th>
<th align="center">AMBP</th>
<th align="center">Systolic</th>
<th align="center">Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">Saline (0.9%)</td>
<td align="center">5 ml</td>
<td align="center">115 ±<break/>7.8</td>
<td align="center">104 ±<break/>1.1</td>
<td align="center">115 ± 6.8</td>
<td align="center">102 ±9.1</td>
<td align="center">00 ±<break/>2.0</td>
<td align="center">02.0 ± 2.0</td>
<td align="center">00 ±<break/>2.0</td>
<td align="center">1.9 ±<break/>0.2</td>
</tr>
<tr>
<td align="center">Propranolol</td>
<td align="center">10 mg</td>
<td align="center">111.5 ±8.5</td>
<td align="center">96 ±<break/>10.6</td>
<td align="center">98.0 ± 7.0</td>
<td align="center">085 ± 7.2</td>
<td align="center">13.2 ±<break/>2.2</td>
<td align="center">11.0 ±3.0</td>
<td align="center">11.70 ± 2.9</td>
<td align="center">11.20± 1.2</td>
</tr>
<tr>
<td align="center">Atenolol</td>
<td align="center">10 mg</td>
<td align="center">119.0 ±7.8</td>
<td align="center">105.0 ± 9.0</td>
<td align="center">105 ± 6.0</td>
<td align="center">093 ± 7.5</td>
<td align="center">14.5 ± 2.0</td>
<td align="center">12.0 ±1.7</td>
<td align="center">11.76± 1.6</td>
<td align="center">11.42 ± 1.3</td>
</tr>
<tr>
<td align="center">(1a)</td>
<td align="center">3 mg</td>
<td align="center">115.5 ± 1.3</td>
<td align="center">100.5 ± 1.7</td>
<td align="center">103.1 ± 1.0</td>
<td align="center">080 ± 1.2</td>
<td align="center">13.5 ± 1.4</td>
<td align="center">21.0 ± 2.7</td>
<td align="center">11.30 ± 1.7</td>
<td align="center">21.00 ± 2.2</td>
</tr>
<tr>
<td align="center">(1b)</td>
<td align="center">2.8mg</td>
<td align="center">117.0 ± 4.7</td>
<td align="center">104.6 ± 4.5</td>
<td align="center">095 ± 2.6</td>
<td align="center">078 ± 4.0</td>
<td align="center">22.0 ± 2.5</td>
<td align="center">26.5 ±2.1</td>
<td align="center">18.80 ± 2.5</td>
<td align="center">25.40 ± 2.5</td>
</tr>
<tr>
<td align="center">(2)</td>
<td align="center">3 mg</td>
<td align="center">111.0 ±2.2</td>
<td align="center">96.4 ±2.8</td>
<td align="center">097 ± 1.4</td>
<td align="center">070 ± 2.5</td>
<td align="center">14.5 ± 3.2</td>
<td align="center">26.0 ±2.0</td>
<td align="center">12.60 ± 2.0</td>
<td align="center">27.30± 2.8</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>BP = Blood pressure, ASBP = Arterial Systolic Blood Pressure, AMBP = Arterial Mean Blood</p></fn>
<fn id="t001fn002"><p>Pressure</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0220920.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220920.t002</object-id>
<label>Table 2</label> <caption><title>Average effect of standard drugs and test compounds (oral route).</title></caption>
<alternatives>
<graphic id="pone.0220920.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0220920.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" rowspan="2">Compounds</th>
<th align="center" rowspan="2">Dose</th>
<th align="center" colspan="2">Pretreated BP- Induced (mmHg)</th>
<th align="center" colspan="2">After1 hr of<break/>Treatment (mmHg)</th>
<th align="center" colspan="2">Change in BP(mmHg)</th>
<th align="center" colspan="2">% Decrease in BP(mmHg)</th>
</tr>
<tr>
<th align="center">ASBP</th>
<th align="center">AMBP</th>
<th align="center">ASBP</th>
<th align="center">AMBP</th>
<th align="center" colspan="2">ASBP</th>
<th align="center" colspan="2">AMBP</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">Saline (0.9%)</td>
<td align="center">5 ml</td>
<td align="center">113.0 ± 2.4</td>
<td align="center">103.0 ± 1.8</td>
<td align="center">109.0 ± 1.7</td>
<td align="center">100.5 ± 1.8</td>
<td align="center">04.0 ± 0.7</td>
<td align="center">02.5 ± 1.5</td>
<td align="center">03.00 ± 1.6</td>
<td align="center">02.20 ± 0.2</td>
</tr>
<tr>
<td align="center">Propranolol</td>
<td align="center">16 mg</td>
<td align="center">112.0 ± 3.9</td>
<td align="center">097.0 ± 2.1</td>
<td align="center">096.5 ± 2.6</td>
<td align="center">081.5 ± 1.7</td>
<td align="center">15.5 ± 1.3</td>
<td align="center">12.0 ± 0.4</td>
<td align="center">11.48 ± 0.5</td>
<td align="center">10.60 ± 1.1</td>
</tr>
<tr>
<td align="center">Atenolol</td>
<td align="center">15 mg</td>
<td align="center">117.5 ± 1.9</td>
<td align="center">105.0 ± 3.6</td>
<td align="center">102.5 ± 1.2</td>
<td align="center">091.0 ± 1.6</td>
<td align="center">15.0 ± 0.7</td>
<td align="center">14.0 ± 2.0</td>
<td align="center">10.71± 1.8</td>
<td align="center">11.52± 1.2</td>
</tr>
<tr>
<td align="center">(1a)</td>
<td align="center">3.5 mg</td>
<td align="center">116.5 ± 3.2</td>
<td align="center">101.0 ± 1.4</td>
<td align="center">099.5 ± 1.9</td>
<td align="center">078.0 ± 1.1</td>
<td align="center">17.0 ± 1.3</td>
<td align="center">23.0 ± 0.3</td>
<td align="center">12.00 ± 0.1</td>
<td align="center">19.00 ± 2.0<break/>1 2.0</td>
</tr>
<tr>
<td align="center">(1b)</td>
<td align="center">3.5 mg</td>
<td align="center">117.0 ± 4.5</td>
<td align="center">102.5 ± 3.3</td>
<td align="center">091.0 ± 3.7</td>
<td align="center">073.5 ± 2.3</td>
<td align="center">26.0 ± 0.8</td>
<td align="center">29.0 ± 1.0</td>
<td align="center">19.20 ± 1.0</td>
<td align="center">24.48 ± 2.5</td>
</tr>
<tr>
<td align="center">(2)</td>
<td align="center">4 mg</td>
<td align="center">111.5 ± 2.8</td>
<td align="center">097.5 ± 2.2</td>
<td align="center">096.5 ± 1.6</td>
<td align="center">072.5 ± 1.2</td>
<td align="center">15.0 ± 1.2</td>
<td align="center">25.0 ± 1.0</td>
<td align="center">11.34 ± 1.3</td>
<td align="center">20.66 ± 2.1</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>BP = Blood pressure, ASBP = Arterial Systolic Blood Pressure, AMBP = Arterial Mean Blood Pressure</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec020">
<title>Toxicity study</title>
<p>Also these compounds <bold>1a, 1b</bold> and <bold>2</bold> had almost equal or less toxicity profile as the data shown in Tables <bold><xref ref-type="table" rid="pone.0220920.t003">3</xref></bold> and <bold><xref ref-type="table" rid="pone.0220920.t004">4</xref></bold> and <xref ref-type="fig" rid="pone.0220920.g004">Fig 4</xref> clearly indicates the level of different biochemical parameters in comparison to standard drug Propranolol and Atenolol. The compounds did not exhibit any toxicity during testing of antihypertensive activity, as no death of any rat occurred during antihypertensive screening study and the level of different biochemical parameters (urea, creatinine, triglycerides, LDH, GSH, SOD, catalase, TBARS and liver enzymes) were almost equal or less in comparison with standard drugs atenolol and propranolol.</p>
<fig id="pone.0220920.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220920.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Graphical representation of SGOT, SGPT, ALP, Albumin, total protein (Liver function test—i.p. route).</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0220920.g004" xlink:type="simple"/>
</fig>
<table-wrap id="pone.0220920.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220920.t003</object-id>
<label>Table 3</label> <caption><title>Comparison of liver function: Enzyme activity, Alkaline Phosphatase and proteins level.</title></caption>
<alternatives>
<graphic id="pone.0220920.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0220920.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Groups<break/>(n = 5)</th>
<th align="center">Treatment</th>
<th align="center">i. p.<break/>Single<break/>Dose</th>
<th align="center">SGOT units/ml</th>
<th align="center">SGPT<break/>units/ml</th>
<th align="center">ALP<break/>units/ml</th>
<th align="center">Albumin<break/>(g/dl)</th>
<th align="center">Total<break/>Protein<break/>(g/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">1</td>
<td align="center">Normal</td>
<td align="center">—</td>
<td align="center">46.83 ±7.70</td>
<td align="center">37.18 ±5.98</td>
<td align="center">41.79 ± 6.85</td>
<td align="center">3.05 ± 0.26</td>
<td align="center">6.97 ± 0.27</td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">(1a)</td>
<td align="center">3.5 mg</td>
<td align="center">45.37 ±7.91</td>
<td align="center">36.49 ±7.1</td>
<td align="center">43.39 ± 7.94</td>
<td align="center">3.02 ± 0.39</td>
<td align="center">6.28 ± 0.25</td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">(1b)</td>
<td align="center">3.5 mg</td>
<td align="center">46.27 ±4.80</td>
<td align="center">36.95 ±5.73</td>
<td align="center">41.9 ± 5.44</td>
<td align="center">3.19 ± 0.15</td>
<td align="center">6.86 ± 0.37</td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">(2)</td>
<td align="center">4 mg</td>
<td align="center">44.85 ±5.49</td>
<td align="center">37.57 ±6.27</td>
<td align="center">44.28 ± 7.22</td>
<td align="center">2.96 ± 0.43</td>
<td align="center">5.98 ± 0.33</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>SGOT = Serum Glutamic Oxaloacetic Transaminase; SGPT = Serum Glutamic Pyruvate transaminase; ALP = Alkaline Phosphatase; i. p. = Intraperitonially; P &gt; 0.05 non-significant. Values are mean ± S.D. (n = 5). ANOVA followed by Dennett's test</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0220920.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220920.t004</object-id>
<label>Table 4</label> <caption><title>Level of different parameters in serum found at Tmax after oral administration of test compounds and standard drugs atenolol [<xref ref-type="bibr" rid="pone.0220920.ref025">25</xref>–<xref ref-type="bibr" rid="pone.0220920.ref029">29</xref>] and propranolol [<xref ref-type="bibr" rid="pone.0220920.ref030">30</xref>–<xref ref-type="bibr" rid="pone.0220920.ref033">33</xref>].</title></caption>
<alternatives>
<graphic id="pone.0220920.t004g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0220920.t004" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" rowspan="3">S. No.</th>
<th align="center" rowspan="3">Test</th>
<th align="center" rowspan="3">Control group</th>
<th align="center" colspan="3">(1b)</th>
<th align="center" colspan="3">(2)</th>
<th align="center" colspan="3">(1a)</th>
<th align="center" colspan="2">Atenolol</th>
<th align="center" colspan="2">Propranolol</th>
</tr>
<tr>
<th align="center" colspan="3">mg/kg</th>
<th align="center" colspan="3">mg/kg</th>
<th align="center" colspan="3">mg/kg</th>
<th align="center" colspan="2">mg/kg<break/></th>
<th align="center" colspan="2">mg/kg<break/></th>
</tr>
<tr>
<th align="center">25</th>
<th align="center">50</th>
<th align="center">100</th>
<th align="center">25</th>
<th align="center">50</th>
<th align="center">100</th>
<th align="center">25</th>
<th align="center">50</th>
<th align="center">100</th>
<th align="center">W/O</th>
<th align="center">With</th>
<th align="center">W/O</th>
<th align="center">With</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center">1</td>
<td align="center">Urea<break/>(mg/dl)</td>
<td align="center">17.6</td>
<td align="center">19.90</td>
<td align="center">19.43</td>
<td align="center">29.00</td>
<td align="center">18.80</td>
<td align="center">26.40</td>
<td align="center">23.53</td>
<td align="center">25.00</td>
<td align="center">23.50</td>
<td align="center">23.53</td>
<td align="center">180±98<xref ref-type="table-fn" rid="t004fn002">*</xref></td>
<td align="center">229±111<xref ref-type="table-fn" rid="t004fn002">*</xref></td>
<td align="center">16.5±1.1<xref ref-type="table-fn" rid="t004fn005">#</xref></td>
<td align="center">16.0 ± 0.4<xref ref-type="table-fn" rid="t004fn005">#</xref></td>
</tr>
<tr>
<td align="center">2</td>
<td align="center">Creatinine<break/>(mg/dl)</td>
<td align="center">0.56</td>
<td align="center">0.56</td>
<td align="center">0.56</td>
<td align="center">0.56</td>
<td align="center">0.4</td>
<td align="center">0.4</td>
<td align="center">0.56</td>
<td align="center">0.73</td>
<td align="center">0.73</td>
<td align="center">0.73</td>
<td align="center">1.6±0.1<xref ref-type="table-fn" rid="t004fn003">**</xref></td>
<td align="center">1.6±0.18<xref ref-type="table-fn" rid="t004fn003">**</xref></td>
<td align="center">0.45±0.01<xref ref-type="table-fn" rid="t004fn006">$</xref></td>
<td align="center">0.42± 0.01<xref ref-type="table-fn" rid="t004fn006">$</xref></td>
</tr>
<tr>
<td align="center">3</td>
<td align="center">TG<break/>(mg/dl)</td>
<td align="center">98.76</td>
<td align="center">101.00</td>
<td align="center">76.53</td>
<td align="center">104.30</td>
<td align="center">97.66</td>
<td align="center">103.23</td>
<td align="center">107.66</td>
<td align="center">101.00</td>
<td align="center">101.00</td>
<td align="center">118.80</td>
<td align="center">129.83±6.04<xref ref-type="table-fn" rid="t004fn004">***</xref></td>
<td align="center">160.83±6.97<xref ref-type="table-fn" rid="t004fn004">***</xref></td>
<td align="center">114±7.0<xref ref-type="table-fn" rid="t004fn011">d</xref></td>
<td align="center">64.1± 4.2<xref ref-type="table-fn" rid="t004fn011">d</xref></td>
</tr>
<tr>
<td align="center">4</td>
<td align="center">ACH<break/>(mU/ml)</td>
<td align="center">10</td>
<td align="center">10</td>
<td align="center">10</td>
<td align="center">10</td>
<td align="center">10</td>
<td align="center">10</td>
<td align="center">10</td>
<td align="center">10</td>
<td align="center">10</td>
<td align="center">10</td>
<td align="center" colspan="2">NR</td>
<td align="center" colspan="2">NR</td>
</tr>
<tr>
<td align="center">5</td>
<td align="center">LDH (μU)</td>
<td align="center">123.00</td>
<td align="center">128.53</td>
<td align="center">61.90</td>
<td align="center">184.10</td>
<td align="center">195.20</td>
<td align="center">117.43</td>
<td align="center">89.66</td>
<td align="center">123.00</td>
<td align="center">173.00</td>
<td align="center">89.66</td>
<td align="center"><xref ref-type="table-fn" rid="t004fn008">a</xref>737.22 + 29.61</td>
<td align="center"><xref ref-type="table-fn" rid="t004fn008">a</xref>759.0 3 + 10.30</td>
<td align="center">112±8<xref ref-type="table-fn" rid="t004fn006">^</xref></td>
<td align="center">131±12<xref ref-type="table-fn" rid="t004fn006">^</xref></td>
</tr>
<tr>
<td align="center">6</td>
<td align="center">GSH (μM)</td>
<td align="center">4.72</td>
<td align="center">6.05</td>
<td align="center">5.03</td>
<td align="center">7.14</td>
<td align="center">5.63</td>
<td align="center">7.01</td>
<td align="center">5.39</td>
<td align="center">7.44</td>
<td align="center">7.44</td>
<td align="center">5.33</td>
<td align="center" colspan="2"><xref ref-type="table-fn" rid="t004fn009">b</xref>No changes up to10 μM</td>
<td align="center" colspan="2"><xref ref-type="table-fn" rid="t004fn009">b</xref>glutathione losses were attenuated 15 to 80%, with EC(50) = 3.1 μM</td>
</tr>
<tr>
<td align="center">7</td>
<td align="center">SOD(U/ml)</td>
<td align="center">2.51</td>
<td align="center">3.17</td>
<td align="center">2.64</td>
<td align="center">2.84</td>
<td align="center">2.84</td>
<td align="center">2.84</td>
<td align="center">2.78</td>
<td align="center">2.52</td>
<td align="center">2.51</td>
<td align="center">2.84</td>
<td align="center">12.27+2.65<xref ref-type="table-fn" rid="t004fn008">a</xref></td>
<td align="center">12.79+0.86<xref ref-type="table-fn" rid="t004fn008">a</xref></td>
<td align="center">2.51±0.08<xref ref-type="table-fn" rid="t004fn010">c</xref></td>
<td align="center">4.93±0.04<xref ref-type="table-fn" rid="t004fn010">c</xref></td>
</tr>
<tr>
<td align="center">8</td>
<td align="center">Catalase (μM)</td>
<td align="center">118.94<break/></td>
<td align="center">96.27</td>
<td align="center">99.11</td>
<td align="center">121.77</td>
<td align="center">113.27</td>
<td align="center">121.77</td>
<td align="center">107.61</td>
<td align="center">113.27</td>
<td align="center">101.94</td>
<td align="center">101.94</td>
<td align="center">16.96+0.86<xref ref-type="table-fn" rid="t004fn008">a</xref></td>
<td align="center">36.92+0.81<xref ref-type="table-fn" rid="t004fn008">a</xref></td>
<td align="center">3.26±0.05<xref ref-type="table-fn" rid="t004fn010">c</xref></td>
<td align="center">4.96±0.08<xref ref-type="table-fn" rid="t004fn010">c</xref></td>
</tr>
<tr>
<td align="center">9</td>
<td align="center">TBARS (μM)</td>
<td align="center">24.01</td>
<td align="center">14.62</td>
<td align="center">15.68</td>
<td align="center">16.13</td>
<td align="center">13.40</td>
<td align="center">15.98</td>
<td align="center">14.62</td>
<td align="center">15.53</td>
<td align="center">14.62</td>
<td align="center">16.59</td>
<td align="center">20.33+1.45<xref ref-type="table-fn" rid="t004fn008">a</xref></td>
<td align="center">17.33+0.88<xref ref-type="table-fn" rid="t004fn008">a</xref></td>
<td align="center" colspan="2"><xref ref-type="table-fn" rid="t004fn007">@No</xref> changes at 10 mg/kg</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p>W/O = without treated, W/T = treated, NR = not reported</p></fn>
<fn id="t004fn002"><p>* = Level of blood urea nitrogen (BUN) at 80mg/kg per day in renal mass reduced rats</p></fn>
<fn id="t004fn003"><p>** 10 mg/kg daily up to 6 weeks</p></fn>
<fn id="t004fn004"><p>*** = in streptozotocin induced diabetic rats at dose of 10mg/kg up to 8 weeks</p></fn>
<fn id="t004fn005"><p># (level of urea nitrogen)</p></fn>
<fn id="t004fn006"><p>$, ^ (U/L) = in plasma with propranolol treatment at 10mg/kg</p></fn>
<fn id="t004fn007"><p>@ = in cyclosporine A—induced oxidative stress and renal dysfunction</p></fn>
<fn id="t004fn008"><p>a = in heart tissue homogenate (LDH in serum- U/L) in isoproteronol induced myocardial damage with atenolol treatment at 6mg/kg (U/mg protein)</p></fn>
<fn id="t004fn009"><p>b = in iron overloaded and oxidative stressed endothelial cells (ECs)</p></fn>
<fn id="t004fn010"><p>c = in heart tissue homogenate at 10 mg/kg propranolol treatment for 7 days U/mg protein)</p></fn>
<fn id="t004fn011"><p>d = in plasma at 25 mg/kg.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec021">
<title>Molecular docking study</title>
<p>Molecular docking on all the three synthesized compounds was performed against <italic>β</italic>1 adrenoreceptor and the docking studies revealed a common binding orientation of all the synthesized compounds in the catalytic binding pocket of <italic>β</italic>1 adrenoreceptor. The amino alkyl moiety plays an important role in the binding, as the carbonyl oxygen, nitrogen atom are involved in hydrogen bonding interactions with amino acid residue Tyr207, Ser212, Asn310, Phe201, Asn329 at the catalytic site as shown in <xref ref-type="fig" rid="pone.0220920.g005">Fig 5</xref> and ligplot (<xref ref-type="fig" rid="pone.0220920.g006">Fig 6</xref>). A pi-pi stacking interaction was also observed between phenyl ring of the xanthone moiety and the phenyl ring of the amino acid residue Phe201 and Tyr207 in all the compounds. In addition, the phenyl group moiety showed hydrophobic interaction with β1 adrenoreceptor protein Tyr333, Phe201, Ser173 and Phe307 amino acid residues. The comparison of binding pose of compound 1b and propranolol with <italic>β</italic>1 adrenoreceptor protein was also reported (Figs <xref ref-type="fig" rid="pone.0220920.g007">7</xref> and <xref ref-type="fig" rid="pone.0220920.g008">8</xref>).</p>
<fig id="pone.0220920.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220920.g005</object-id>
<label>Fig 5</label>
<caption>
<title>The binding mode of 1b (grey) in the <italic>β</italic>1 adrenoreceptor active site.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0220920.g005" xlink:type="simple"/>
</fig>
<fig id="pone.0220920.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220920.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Ligplot of 1b with <italic>β</italic>1 receptor active site.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0220920.g006" xlink:type="simple"/>
</fig>
<fig id="pone.0220920.g007" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220920.g007</object-id>
<label>Fig 7</label>
<caption>
<title>Binding pattern of propranolol with <italic>β</italic>1.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0220920.g007" xlink:type="simple"/>
</fig>
<fig id="pone.0220920.g008" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0220920.g008</object-id>
<label>Fig 8</label>
<caption>
<title>Comparison of 1b (green) and propranolol ligand (grey) binding mode in the <italic>β</italic>1 active site.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0220920.g008" xlink:type="simple"/>
</fig>
<p>For better understanding of binding mode of amino alkyl substituted xanthone derivatives at the molecular level, we carried out molecular docking simulations of all the three synthesized molecules at the β1 adrenoreceptor catalytic ligand binding site. The docking score for the compound <bold>1b</bold> was found <bold>-9.1</bold> while for compound <bold>1a</bold> and <bold>2</bold> were found <bold>-8.7</bold> and <bold>-8.6</bold> respectively.</p>
</sec>
</sec>
<sec id="sec022" sec-type="conclusions">
<title>Conclusions</title>
<p>It was observed during the studies that these novel compounds i.e. 1a, 1b, and 2 have greater antihypertensive activity in comparison to standard drugs Propranolol and Atenolol, as these compounds showed greater percentage of reduction in both systolic and mean blood pressure. The compounds did not exhibit any toxicity during study, as no death of any rat occurred during antihypertensive screening study and the level of different biochemical parameters (urea, creatinine, etc.) were almost equal or less in comparison with standard drugs atenolol and propranolol. The binding of these synthesized compounds with beta adrenoceptors were better than Propranolol, as the docking score for these compounds were found to be <bold>-9.1</bold> for 1b while for compound <bold>1a</bold> and <bold>2</bold> were found to be <bold>-8.7</bold> and <bold>-8.6</bold> respectively. Thus, it concludes that these compounds can be used as lead molecules for future investigations.</p>
</sec>
</body>
<back>
<ack>
<p>The authors are thankful to the Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India for providing all facilities to conduct this experimental work.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0220920.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hay</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Helesbeux</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Duval</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Labaied</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Grellier</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Richomme</surname> <given-names>P</given-names></name>. <article-title>Antimalarial xanthones from Calophyllumcaledonicum and Garcinia vieillardii</article-title>. <source>Life Sci</source>. <year>2004</year>; <volume>75</volume>: <fpage>3077</fpage>–<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.lfs.2004.07.009" xlink:type="simple">10.1016/j.lfs.2004.07.009</ext-link></comment> <object-id pub-id-type="pmid">15474559</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Marona</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Pekala</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Antkiewicz-Michaluk</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Walczak</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Szneler</surname> <given-names>E</given-names></name>. <article-title>Anticonvulsant activity of some xanthone derivatives</article-title>. <source>Bioorg. Med. Chem</source>. <year>2008</year>; <volume>16</volume>: <fpage>7234</fpage>–<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bmc.2008.06.039" xlink:type="simple">10.1016/j.bmc.2008.06.039</ext-link></comment> <object-id pub-id-type="pmid">18640843</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Na</surname> <given-names>Y</given-names></name>. <article-title>Recent cancer drug development with xanthone structures</article-title>. <source>J. Pharm. Pharmacol</source>. <year>2009</year>; <volume>61</volume>: <fpage>707</fpage>–<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1211/jpp/61.06.0002" xlink:type="simple">10.1211/jpp/61.06.0002</ext-link></comment> <object-id pub-id-type="pmid">19505360</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zou</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Ma</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>WB</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Z</given-names></name>. <article-title>Xu. Synthesis and pharmacological activities of xanthone derivatives as a-glucosidase inhibitors</article-title>. <source>Bioorg. Med. Chem</source>. <year>2006</year>; <volume>14</volume>: <fpage>5683</fpage>–<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bmc.2006.04.014" xlink:type="simple">10.1016/j.bmc.2006.04.014</ext-link></comment> <object-id pub-id-type="pmid">16651002</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Blanco-Ayala</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Lugo-Huitrón</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Serrano-Lopez</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Reyes-Chilpa</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Rangel-Lopez</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Pineda</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Antioxidant properties of xanthones from Calophyllumbrasiliense: prevention of oxidative damage induced by FeSO4</article-title>. <source>BMC Complement. Altern. Med</source>. <year>2013</year>; <volume>13</volume>: <fpage>262</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1472-6882-13-262" xlink:type="simple">10.1186/1472-6882-13-262</ext-link></comment> <object-id pub-id-type="pmid">24119308</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gutierrez-Orozco</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Failla</surname> <given-names>ML</given-names></name>. <article-title>Biological Activities and Bioavailability of Mangosteen Xanthones: A Critical Review of the Current Evidence</article-title>. <source>Nutrients</source>. <year>2013</year>; <volume>5</volume>: <fpage>3163</fpage>–<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/nu5083163" xlink:type="simple">10.3390/nu5083163</ext-link></comment> <object-id pub-id-type="pmid">23945675</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Marona</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Librowski</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Cegła</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Erdogan</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Sahin</surname> <given-names>NO</given-names></name>. <article-title>Antiarrhythmic and antihypertensive activity of some xanthone derivatives</article-title>. <source>Acta. Pol. Pharm</source>. <year>2008</year>; <volume>65</volume>: <fpage>383</fpage>–<lpage>90</lpage>. <object-id pub-id-type="pmid">18646559</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Kang</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Teng</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Lina</surname> <given-names>C</given-names></name>. <article-title>Antihypertensive and Vasorelaxing Activities of Synthetic Xanthone Derivatives</article-title>. <source>Bioorg. Med. Chem</source>. <year>2002</year>; <volume>10</volume>: <fpage>567</fpage>–<lpage>72</lpage>. <object-id pub-id-type="pmid">11814844</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref009"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ahmed B. 2012; Indian Patent No. 250538. Delhi, India: Indian patent office.</mixed-citation></ref>
<ref id="pone.0220920.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jorgensen</surname> <given-names>WL</given-names></name>. <article-title>Rusting of the lock and key model for protein-ligand binding</article-title>. <source>Science.</source> <year>1991</year>; <volume>254</volume>: <fpage>954</fpage>–<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.1719636" xlink:type="simple">10.1126/science.1719636</ext-link></comment> <object-id pub-id-type="pmid">1719636</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grover</surname> <given-names>PK</given-names></name>, <name name-style="western"><surname>Shah</surname> <given-names>GD</given-names></name>, <name name-style="western"><surname>Shah</surname> <given-names>RC</given-names></name>. <article-title>A new synthesis of hydroxyxanthones and hydroxybenzophenones</article-title>. <source>J. Chem. Soc</source>. <year>1955</year>; <volume>0</volume>: <fpage>3982</fpage>–<lpage>5</lpage>.</mixed-citation></ref>
<ref id="pone.0220920.ref012"><label>12</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Ghosh</surname> <given-names>MU</given-names></name>. <chapter-title>Fundamentals of Experimental Pharmacology</chapter-title>. <publisher-name>Scientific Book Agency</publisher-name>, <publisher-loc>Calcutta</publisher-loc>, <year>1994</year>.</mixed-citation></ref>
<ref id="pone.0220920.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ahmed</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Khan</surname> <given-names>SA</given-names></name>. <article-title>Antihepatotoxic Activity of Flavolignans of seeds of Silybummarianum</article-title>. <source>OCAIJ</source>. <year>2003</year>; <volume>1</volume>: <fpage>47</fpage>–<lpage>52</lpage>.</mixed-citation></ref>
<ref id="pone.0220920.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ashwood</surname> <given-names>ER</given-names></name>, <name name-style="western"><surname>Tietz</surname> <given-names>NW</given-names></name>, <name name-style="western"><surname>Burtis</surname> <given-names>CA</given-names></name>. <article-title>Kidney function test: Creatinine clearance, Tietz Textbook of clinical chemistry</article-title>. Saunders, Philadelphia, <year>1994</year>.</mixed-citation></ref>
<ref id="pone.0220920.ref015"><label>15</label><mixed-citation publication-type="book" xlink:type="simple"><name name-style="western"><surname>Teitz</surname> <given-names>NW</given-names></name>. <chapter-title>Clinical guide to laboratory tests (Urea)</chapter-title>. <publisher-name>WB Saunders Co</publisher-name>., <publisher-loc>Philadelphia</publisher-loc>, <year>1976</year>.</mixed-citation></ref>
<ref id="pone.0220920.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Buduneli</surname> <given-names>E</given-names></name>. <article-title>Systemic Low-Dose Doxycycline and Alendronate Administration and Serum Interleukin-1Beta, Osteocalcin, and C—reactive protein Levels in Rats (Cardiac Functions test; C Reactive protein</article-title>. <source>J. Periodontol</source>. <year>2005</year>; <volume>76</volume>: <fpage>1927</fpage>–<lpage>33</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1902/jop.2005.76.11.1927" xlink:type="simple">10.1902/jop.2005.76.11.1927</ext-link></comment> <object-id pub-id-type="pmid">16274312</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>King</surname> <given-names>J</given-names></name>. <article-title>Practical and clinical enzymology (LDH).</article-title> Van Nostrand, London, <year>1965</year>.</mixed-citation></ref>
<ref id="pone.0220920.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Warnick</surname> <given-names>GR</given-names></name>, <name name-style="western"><surname>Nguyen</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Albers</surname> <given-names>AA</given-names></name>. <article-title>Lipid Profile, LDL/HDL Cholesterol, Comparison of improved method for quantification of HDL cholesterol</article-title>. <source>Clin. Chem</source>.<year>1985</year>; <volume>31</volume>: <fpage>217</fpage>–<lpage>22</lpage>. <object-id pub-id-type="pmid">2578337</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wybenga</surname> <given-names>DR</given-names></name>, <name name-style="western"><surname>Pileggi</surname> <given-names>VJ</given-names></name>, <name name-style="western"><surname>Dirstine</surname> <given-names>PH</given-names></name>, <name name-style="western"><surname>Di Georgio</surname> <given-names>J</given-names></name>. <article-title>Direct manual determination of serum total cholesterol with a single stable reagent</article-title>. <source>Clin. Chem</source>. <year>1970</year>; <volume>16</volume>: <fpage>980</fpage>–<lpage>84</lpage>. <object-id pub-id-type="pmid">4098216</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Trinder</surname> <given-names>P</given-names></name>. <article-title>Determination of triglycerides</article-title>. <source>Ann. Clin. Biochem</source>. <year>1969</year>; <volume>6</volume>: <fpage>24</fpage>–<lpage>7</lpage>.</mixed-citation></ref>
<ref id="pone.0220920.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Friedwalds</surname> <given-names>WT</given-names></name>, <name name-style="western"><surname>Levy</surname> <given-names>RT</given-names></name>, <name name-style="western"><surname>Friedickson</surname> <given-names>DS</given-names></name>. <article-title>Estimation of concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge</article-title>. <source>Clin. Chem</source>. <year>1972</year>; <volume>18</volume>: <fpage>499</fpage>–<lpage>502</lpage>. <object-id pub-id-type="pmid">4337382</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ellman</surname> <given-names>GL</given-names></name>, <name name-style="western"><surname>Courtny</surname> <given-names>KD</given-names></name>, <name name-style="western"><surname>Valentino</surname> <given-names>A</given-names> <suffix>Jr.</suffix></name> <article-title>A new and rapid method for determination of tissue Acetyl cholinesterase activity</article-title>. <source>Biochem. Pharmacol</source>. <year>1961</year>; <volume>7</volume>: <fpage>88</fpage>–<lpage>99</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/0006-2952(61)90145-9" xlink:type="simple">10.1016/0006-2952(61)90145-9</ext-link></comment> <object-id pub-id-type="pmid">13726518</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Feldman</surname> <given-names>E</given-names></name>. <article-title>Thiobarbituric acid reactive substances (TBARS) Assay, Animal Models of Diabetic Complications Consortium (AMDCC Protocols).</article-title> <year>2004</year>; <fpage>1</fpage>–<lpage>3</lpage>.</mixed-citation></ref>
<ref id="pone.0220920.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>LW</given-names></name>, <name name-style="western"><surname>Kang</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>IJ</given-names></name>, <name name-style="western"><surname>Teng</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Lin</surname> <given-names>CN</given-names></name>. <article-title>Antihypertensive and vasorelaxing activities of synthetic xanthone derivatives</article-title>.<source>Bioorg. Med. Chem.</source> <year>2002</year>; <volume>10</volume>:<fpage>567</fpage>–<lpage>72</lpage>. <object-id pub-id-type="pmid">11814844</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pires</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Rodriguez–Pena</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Colaco</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Arevalo</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Esteller</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lopez-Novoa</surname> <given-names>JM</given-names></name>. <article-title>Comparative effects of nebivolol and atenolol on renal functionin rats with chronic renal failure</article-title>. <source>Port. J. Nephrol. Hypert</source>. <year>2010</year>; <volume>24</volume>: <fpage>33</fpage>–<lpage>43</lpage>.</mixed-citation></ref>
<ref id="pone.0220920.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goyal</surname> <given-names>BR</given-names></name>, <name name-style="western"><surname>Bhadada</surname> <given-names>SV</given-names></name>, <name name-style="western"><surname>Patel</surname> <given-names>MM</given-names></name>. <article-title>Comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril on diabetes-induced cardiovascular complications in type 1diabetes in rats.</article-title> <source>Int. J. Diabetes &amp; Metab</source>. <year>2011</year>; <volume>19</volume>: <fpage>11</fpage>–<lpage>8</lpage>.</mixed-citation></ref>
<ref id="pone.0220920.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Prajapati</surname> <given-names>AR</given-names></name>, <name name-style="western"><surname>Patel</surname> <given-names>BK</given-names></name>, <name name-style="western"><surname>Patel</surname> <given-names>PM</given-names></name>. <article-title>Comparison of effects of atenelol, carvedilol, and nebivelol on strepetozotocin induced diabetes associated with cardiovascular complications.</article-title> <source>ijprb</source>, <year>2012</year>; <volume>1</volume>: <fpage>396</fpage>–<lpage>410</lpage>.</mixed-citation></ref>
<ref id="pone.0220920.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Avula</surname> <given-names>PR</given-names></name>, <name name-style="western"><surname>Asdaq</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Asad</surname> <given-names>M</given-names></name>. <article-title>Effect of aged garlic extract and s-allyl cysteine and their interaction with atenolol during isoproterenol induced myocardial toxicity in rats</article-title>. <source>Indian J. Pharmacol</source>. <year>2014</year>; <volume>46</volume>: <fpage>94</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4103/0253-7613.125185" xlink:type="simple">10.4103/0253-7613.125185</ext-link></comment> <object-id pub-id-type="pmid">24550592</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>MakI</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Chmielinska</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Nedelec</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Torres</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Weglicki</surname> <given-names>WB</given-names></name>. <article-title>D-propranolol attenuates lysosomal iron accumulation and oxidative injury in endothelial cells</article-title>. <source>J. Pharmacol. Exp. Ther</source>. <year>2006</year>; <volume>317</volume>: <fpage>522</fpage>–<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1124/jpet.105.097709" xlink:type="simple">10.1124/jpet.105.097709</ext-link></comment> <object-id pub-id-type="pmid">16456084</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arakawa</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kodama</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Matsuoka</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Yamaguchi</surname> <given-names>I</given-names></name>. <article-title>Stress Increases Plasma Enzyme Activity in Rats: Differential Effects of Adrenergic and Cholinergic Blockades</article-title>. <source>J. Pharmacol. Exp. Ther</source>. <year>1997</year>; <volume>280</volume>: <fpage>1296</fpage>–<lpage>303</lpage>. <object-id pub-id-type="pmid">9067316</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Asdaq</surname> <given-names>SMB</given-names></name>, <name name-style="western"><surname>Inamdar</surname> <given-names>MN</given-names></name>. <article-title>Interaction of Propranolol with Garlic on Biochemical and Histological Changes in Rat.</article-title> <source>Iran. J. Pharm. Res</source>. <year>2009</year>; <volume>8</volume>: <fpage>201</fpage>–<lpage>7</lpage>.</mixed-citation></ref>
<ref id="pone.0220920.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Padi</surname> <given-names>SSV</given-names></name>, <name name-style="western"><surname>Chopra</surname> <given-names>K</given-names></name>. <article-title>Salvage of Cyclosporine A-Induced Oxidative Stress and Renal Dysfunction by Carvedilol</article-title>. <source>Nephron</source>. <year>2002</year>; <volume>92</volume>: <fpage>685</fpage>–<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000064095" xlink:type="simple">10.1159/000064095</ext-link></comment> <object-id pub-id-type="pmid">12372956</object-id></mixed-citation></ref>
<ref id="pone.0220920.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kunihara</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Oshima</surname> <given-names>T</given-names></name>. <article-title>Effects of epinephrine on plasma cholesterol levels in rats</article-title>. <source>J. Lipid Res</source>. <year>1983</year>; <volume>24</volume>: <fpage>639</fpage>–<lpage>44</lpage>. <object-id pub-id-type="pmid">6308112</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>